text:
Christie helps 3D shine at IBC
IBC (Amsterdam, The Netherlands) will focus on 3D on monday 12 September 2011.
Christie's next generation of 2K and 4K DLP Cinema projection systems will be used to support all presentations at the IBC Big Screen Experience throughout the show, including the Big Screen Saturday Night Movie: Transformers 3: Dark Of The Moonin Digital 3D (RAI Auditorium, September 10), and the D-Cinema Conference in the RAI Theatre on September 12th, which centres on all things 3D — from post-production to live transmission.
Dr Don Shaw, Director, Product Management for Christie's Entertainment Solutions Division will present Exhibitor Considerations for High Frame Rate 3D Technology as part of the IBC "A Stereoscopic Glimpse into the Future" session, immediately prior to Cameron's September 12th presentation. This latter presentation will showcase some of the latest digital 3D content including and an amazing 18-minute reel of James Cameron's Titanic in 3D; Flying Monsters and The Royal Wedding.
The Christie P.R. is on PRNewswire.


text:
Microsoft will go head-to-head with Apple in the booming tablet computer market after the software company revealed plans to introduce a new product, the Surface.
The device, which was unveiled at a much-hyped event in Los Angeles last night, has a 10.6in display and is under half an inch thick. It was designed specifically for Microsoft's operating systems and features a case that turns into a keyboard, a built-in stand and USB port. Its price will be announced closer to the launch date, which will be later this year.
Microsoft has already made a move into the tablet sector having spent $300 million to take a stake in the digital operations of Barnes & Noble, the world's largest physical bookstore. B&N's Nook tablet is expected…

subset: commoncrawl


text:
'Tis the season
For the sights, sounds and tastes of a traditional Christmas, visit Europe's best Christmas markets.
For the sights, sounds and tastes of a traditional Christmas, visit Europe's best Christmas markets.
Visit the Magic of Advent – the largest Christmas market in Vienna, which takes place in front of the City Hall.
For a true winter wonderland setting visit the illuminated Christmas markets in Prague.
Experience the magical Christmas charm in Berlin. With a choice of 60 Christmas markets, you'll find something for everyone.
Experience a white Christmas at Krakow's Old Town Christmas markets.
Begin your festivities a little earlier this year and discover spectacular Christmas markets all over Europe. Search for hand-made gifts and trinkets, weave through illuminated stalls and sip hot chocolate or mulled wine as you get into the Christmassy spirit.
Start the annual festive fun with a city break to one of Europe's most picturesque destinations. Enjoy a wintry taste of tradition as you visit time-honoured Christmas markets and shop for local wares – all against a wonderful setting. You could even treat yourself to a Club Europe break and fly in our business class cabin.
The Christmas markets in the UK grow in size and popularity every year, and London leads the way. They are plenty to chose from; why go to just one?
As well as London, you can travel further afield across the length and breadth of the UK. Christmas markets are appearing in many UK cities and towns, so there will always be one not too far from you.
The German capital's 60-plus Christmas markets will have something for everyone. From the spectacular WeihnachtsZauber at the Gendarmenmarkt, one of the most popular markets in Berlin, to the wonderful Winter World at Potsdamer Platz. Head to Alexanderplatz Christmas market to see Europe's largest Christmas pyramid – all under the gaze of the famous TV Tower.
Christmas markets in Prague are some of the most beautiful in Europe, and the well-known markets are held in the Old Town Square (Staroměstské náměstí) and the Havelska market (Havelské tržiště). You'll find the national Christmas tree in the former, amid beautiful baroque architecture. While Havelska market is the oldest in Prague, dating back to the 13th century.
Venture outside of the Czech capital to find even more beautiful Christmas markets and enjoy Bohemian trdelník (sweet pastry) with Christmas punch. Head to Český Krumlov, just two hours south of Prague for a traditional Czech Advent, including their astonishing live Nativity scene. The picturesque streets come alive with merrymakers drinking mulled wine, singing carols by the giant Christmas tree. Or visit the beautiful town of Plzeň, home of the famous Pilsen beer. Only an hour and half by car, you can be enjoying the city's lively folk music and carols by the Tree, warming yourself with freshly baked Christmas treats.
Vienna's Christmas markets are an age-old part of the city, with the earliest dating back to 1298 when Albrecht I granted his citizens a December market. Now, they are held all over the city, and are well worth a visit – in particular the Viennese Christmas Market in front of the City Hall. Find handcrafted gifts, delectable culinary treats and all the glühwein you can drink.
Christmas markets in Budapest are spellbinding, with the oldest and most captivating being on Vörösmarty Square – but don't miss a trip to the market outside St Stephen's Basilica too. Gifts like the handmade wooden toys are made in Hungary, ensuring their quality. As autumn becomes winter, you'll be very glad of the warming mulled wine and cinnamon chimney cakes.
The stunning Cathedral Square is the location for Salzburg's Christmas market – and with its traditional stalls under the twinkling stars, you'll find a charming atmosphere like no other. Search out festive cookies, crafts and the unmissable Salzburg school choirs singing popular hymns and carols. Head to Residence Square on a Saturday for the local Turmblasen brass bands.
Almost guaranteed to be a 'white' Christmas, Krakow is Poland's charming tourist capital. The Main Square (Rynek Główny) in the Old Town comes alive with all things festive. Find handcrafted ornaments, decorations, furs and slippers, and beautiful Baltic amber jewellery, as you stroll through the many stalls. Try the cherry vodka to shake off the winter chill.
Christmas in Innsbruck is wonderful, with carollers singing, huge Christmas trees twinkling and the scent of freshly made cakes and doughnuts hanging in the air. Head to Innsbruck's Old Town for traditional gifts, beautiful ornaments and of course, a delicious mug of Tyrolean glühwein to warm the soul, all surrounded by stunning medieval architecture.
Christmas markets in Zurich are enchanting, from the 50 foot Christmas tree to the city's oldest market in the picturesque Niederdorf Quarter. There are several to choose from, like the huge market at Sechseläutenplatz next to the Opera House or the singing tree (tiers of a children's choir) at the Werdmühleplatz. Grab a mug of hot chocolate and enjoy the festivities for yourself.
Munich's Christmas markets are very traditional, and the market on Marienplatz (St Mary's Square) is the biggest and the oldest, going back to the 14th century. Revellers can enjoy classical Christmas music and hymns from the balcony of Munich's Rathaus (town hall) each evening, alongside traditional gingerbread and Bavarian cakes.
Copenhagen's streets come alive with merrymakers over the Christmas season, especially at the magical Tivoli Gardens. This charming theme park in the centre of the city is an ideal setting for a Christmas market, with around 60 stalls setting up alongside the more permanent residents. Don't forget to get some Gløgg and Æbleskiver, a delicious mulled wine and doughnut combo.
Held at the famous Senate Square, Helsinki's Christmas market is a sight to behold. With over 100 stands selling everything from hand-made crafts and sweets to Finnish canned goods like pickled herring. Get yourself a warming Glögi, Finland's answer to mulled wine, with festive spices, almonds and a dash of vodka to keep the freezing temperatures at bay.
Venture to Frankfurt's Old Town to find the traditional Christmas markets, illuminated by thousands of fairy lights. The scents and smells – gingerbread, mulled wine and roasting chestnuts – of the festive season fill the air. Explore the market, especially the 300-year old timber-framed Honey House, assembled every year offering honey-based goods and even delicious honey wine.
The most northerly capital city in our list, Reykjavík offers arctic festivities at Yule Town on Ingólfstorg Square throughout the Christmas period. With a wide selection of gifts, including handmade knick-knacks and delicious Icelandic treats. Or at the market at Heidmork, you will find designers and craftsmen selling their wares, but only on a few select days, guaranteeing a bespoke item.
There are some great Christmas markets in Stockholm, the oldest is the Skansen on the park island of Djurgården. Founded in 1903, you will find traditional toys and handmade ornaments as well as a large selection of Swedish delicacies to eat and drink. The Stortorget market in Gamla Stan offers superb food under the shadow of the grandiose Stockholm Stock Exchange Building.
Christmas at Disneyland Paris is a spectacular journey, enjoy the festivities with a Christmas parade as all of your favourite Disney characters take to Main Street. Revel in the magic of Sleeping Beauty's castle, which is transformed into an ice palace, and meet Santa Claus in his chalet for a photo opportunity like no other.
Adam Jacot de Boinod, author of The Meaning of Tingo and former researcher for QI, investigates the unique appeal of Europe's best Christmas markets.Read the full article here
Plan and book your holiday with British Airways, online or by phone. Enjoy all these great benefits:


text:
Model Mayhem Admin
SickStarrModel Female Tampa, Florida, US
Mayhem # 37568
About Me
I am a 27 year old costume maker in Tampa FL. I prefer work behind the camera but will model occasionally. I havent signed on to MM in years and it might be a while before I do again.
Have you worked with SickStarr? Add Credits for SickStarr! >>
Model Mayhem Admin
Joe at AE Photography Photographer
Rik Bowman Photographer
Jax Professional Photos Photographer
Clayton Bownds Photographer
KoolGirlie... Photographer
Loading Content


text:
News & Events
Technology and Innovation: Their Effects on Cost Growth of Healthcare
Statement of
Mark B. McClellan, M.D., Ph.D
Commissioner of Food and Drugs
Joint Economic Committee
July 9, 2003
Good morning Mr. Chairman and Members of the Committee. I am Dr. Mark B. McClellan, Commissioner of Food and Drugs, and I welcome this opportunity to testify before the Committee today. As we enter the 21st century, America leads the world in developing and commercializing new medical innovations and technologies. From information technology to biotechnology to materials science, United States (U.S.) scientists and high technology workers are making new discoveries and developing new products every day that are steadily improving the quality of our lives. This progress is critical to our health and our economic prosperity.
Innovations resulting from breakthroughs in science and technology fuel economic growth. According to the Department of Commerce, the information technology sector accounts for just seven percent of all businesses in the U.S. economy, yet between 1996 and 2000, it drove 28 percent of the overall U.S. real economic growth and created jobs at twice the pace of other sectors. These jobs paid twice as much on average as well. Many leading economists now believe that new discoveries in information technology led to investments over the last couple of decades that helped account for the historic surge in economy-wide productivity growth in the 1990s.
While all economists appreciate the contribution of such economic growth to the well-being of the U.S., there is often less appreciation of the contribution of innovations in biomedical technology. A primary reason is that technological change in medicine brings benefits in addition to direct economic gains, including increased longevity, improved quality of life, and less time absent from work. These benefits are not taken into account in standard measures of aggregate economic output. If a country had real gains in its overall health, but not in its material well being (most often measured by per-capita income) the national income accounts would not change, even though those accounts are often thought to measure the well being of a population.i In addition, the direct economic and public health benefits of developing important new medicines often takes considerable time to be realized. If a high-technology firm invents a better memory chip, the time to get that innovation into products sold in the U.S. could potentially be as short as a matter of weeks or months. Regardless of how promising a drug or other new treatment appears in the laboratory or even in animals, it must undergo extensive clinical trials before it can be approved as safe and effective for market introduction.
In recent years, economists have tried to quantify the value of biomedical innovation to society. Some economists actually estimate that the value of the longer and better lives that have resulted from translating new biomedical knowledge into steps to prevent and slow diseases is worth literally many trillions of dollars in better health. In particular, the value of biomedical innovation to the U.S. equals the value of innovation in all other sectors of the American economy combined.ii Even with the benefits of new medical technology, the fact remains that technological innovation is a major source of increase in real per-capita medical spending in the U.S. Innovations in medicine can reduce spending on medical care. For example, treatments ranging from effective care for depression to laser eye surgery are much less expensive than in years past. But many new technologies result in increased costs, and in some instances the net effect of overall technological change has been to raise health care expenditures. First, when a treatment becomes less expensive and safer (fewer complications), more patients may decide that a treatment is worth the risks and unpleasantness. In the early 1980s, relatively few seniors had cataracts removed because the procedure required an unpleasant hospital stay, often had complications, and yielded imperfect results. Today, thanks to improvements in technology, millions more seniors with more modest visual impairment find that modern cataract surgery improves their lives. Second, many treatments exist that do things that simply were not possible before, such as allowing many patients to survive previously fatal or impairing diseases. Americans spend much more on transportation today than they did a century ago because of innovations in transportation ranging from automobiles to airplanes, allow people to go places they simply could not before. Similarly, patients with heart disease, cerebrovascular disease, cancer, arthritis, AIDS, and countless other conditions are living longer and better lives because of medical innovations that transformed fatal illnesses or illnesses that could only be treated with comfort measures into manageable conditions.
The increased spending on health care does not necessarily reflect negatively on technological change. While many studies attribute a large share of the age- and price-adjusted growth in per capita medical spending in recent decades to technological innovation, a key issue is whether the benefits of innovation are rising faster or slower than the costs.
This important question is difficult to answer. It depends on our ability to determine the value of output from the health services sector, and putting a value on a longer life or a higher quality of life is hard to appraise. Nonetheless, a limited number of studies have attempted to aggregate the medical value of new innovations across the whole health care economy in general and the drug industry in particular. Even with these studies, it can be difficult to sort out whether the observed improvements in health are from medical technology, or from other factors that may influence health outcomes, such as higher incomes, improved public health measures, or changes in behavior as a result of greater biomedical knowledge. To try to identify the net value of medical technology itself, several studies have attempted to measure the value of specific kinds of innovations. A number of studies have examined outcomes for specific illnesses, such as heart attacks and depression, where the impact of specific changes in technology can be examined more closely. While none of these studies are completely convincing in themselves, they generally show that medical innovation has greatly increased value, that is, the value of the improved health is far larger than the increase in spending.iii
The reasons are quite intuitive. Individuals are living longer and better lives, because our nation is making real progress in the quality of medical care for many conditions. While the achievements of health improvements in past decades have been impressive, recent progress in genomics, proteomics, nanotechnology, information technology, and many other fields promise even greater improvements in our lives in the years ahead.
We achieved the improvements of the last few decades without a sophisticated science of genomics – the human genome was sequenced in just the last few years. Genomically-based drugs, and gene and tissue therapies based on genomic sciences, are making up a growing number of the new drugs entering clinical trials. We also achieved our recent progress without the new science of proteomics, and an increasingly sophisticated understanding of how gene and protein expression interact to cause disease in individual patients. We also did it without a new generation of increasingly powerful biomedical tools based on the latest information technology that can enable sophisticated systems for supporting effective medical decision-making. These additional tools increase the future potential for more effective, more targeted, even individualized medical treatments that can cure or at least slow or halt disease progression.
As health care costs have gone up, it is increasingly important to make sure we are realizing the full value of the new medical technologies that we create. Maximizing our public health gains and our economic gains from new medical technology also requires that we encourage high value innovations and also realize more value from the products that we use. This is important for the future, because while the cost of new medical technologies may continue to rise, the potential benefits of new treatments could grow even more dramatically.
We must find better ways to increase value, to keep modern care affordable, while still encouraging medical innovation. With these unprecedented technological achievements have also come unprecedented concerns about the total spending on healthcare and, in particular, about the rising spending on these new medical technologies. Many worry that, even if these new technologies come along, they will not benefit because they will not be able to afford the high cost. While we need to take new steps to address the problem of health care affordability, we need to do it carefully. We must address this issue in a way that will not risk the tremendous potential for public health and economic benefits from continuing medical innovation by putting significant new limits on the payments or the intellectual property protections of innovative treatments that have made it through an increasingly long and costly development process.
In particular, there is concern about the threats to innovation because the process of medical innovation – of turning sound ideas from insights in the biomedical laboratory sciences into safe and effective products for treatments – has steadily become more costly. Getting a product into general use is an increasingly lengthy and costly business and fraught with significant risk.iv Some estimates put the total cost of developing a novel drug at more than $800 million, and by all estimates it has increased substantially in the past decade.v Too often, the process is unpredictable, and may take years of hard work with high costs for product testing and developing reliable production lines.vi
Many people involved in the development of new medical technology believe the slowdown in drug approvals is likely to be only temporary. Currently, the National Institutes of Health (NIH) is completing a five-year doubling of its budget, to more than $27 billion. Less well known is that spending on research and development by pharmaceutical companies worldwide has also doubled since 1995 and now is estimated to be more than $54 billion. R&D spending by biotech and medical device companies is also rising. The impact of these investments in research is already becoming evident in the form of more investigational new drugs (INDs) under development than ever.
But if the impact of information technology on the economy is any guide, it may require a decade or more of increased investments in order to have a real impact on productivity - on how much output we get as a result of these inputs. And it could take much longer, because of the unusual length and uncertainty of the product development process in health care. At this point in genomics, for example, scientists are still primarily gathering information, sorting out patterns, and only starting to understand what the turning on or off of hundreds of genes by a new drug means for whether it is safe and effective in patients. The increase in the time and cost of product development has already been associated with a decline in the number of truly new drugs and biological treatments being approved by FDA. Last year, FDA approved 21 new molecular entities (the truly new drugs) down from 44 such entities in 1996. And FDA approved 12 new biological license applications (BLAs), down from 27 BLAs in 1998. The decline in products approved is not the result of FDA rejecting more applications; it is directly related to a decline in the number of new applications for drugs and biologics coming in to the Agency, and it is a worldwide phenomenon.vii
While there are and no doubt will continue to be traditional "blockbuster"-type drugs in development that may bring important public health benefits to many millions of patients, breakthroughs in genomics, proteomics, and other new fields of molecular biology also hold great promise for truly individualized drug therapy in which diagnostic tests and novel drug delivery mechanisms guide the use of medications, turning heterogeneous diseases like cancer and heart disease into distinct types of pathologies that appropriately require distinct therapeutic approaches. Other new technologies are breaking down the traditional barriers between drugs, tissues, and devices, including products in development that are combinations.
Translating the new biomedical sciences into these new kinds of treatments for patients requires major new investments, and it seems plausible that such investments may take many years to reach fruition. It should not be surprising that we haven't yet seen the huge increase in biomedical investment of the past decade, and especially the last few years, turn into more and more valuable medical products for patients. But the fact remains that developers of biomedical products are not producing drugs particularly faster than they were before all these innovations came along. From a public health standpoint, with millions of Americans suffering from diseases that may be curable or at least manageable in the not too distant future, we cannot afford to wait many more years for all these investments to become valuable products.
On the research and development side, it's possible that the costs and uncertainty of developing new treatments could keep rising. It's easy to see how this could happen: there are not many more obvious drug targets left to exploit, and developing genomics- and proteomics-based therapies remains very costly. So far, genomics has mainly added steps at the front end of the development process, through microarray testing of gene responses, and has not reduced the costs of clinical research significantly. On the policy side, there is intense pressure to make health care more affordable, and so policymakers may focus only on reducing medical costs in the short run – which, if not done properly, could reduce the incentive to incur these high and rising development costs. This combination of rising costs of product development and pressures to control costs rather than increase value is not a good one for keeping the United States at the forefront of biomedical innovation, and more importantly it's not a good combination for affordable and high-quality, innovative health care for our population. Instead, a more effective approach would involve bringing costs down by reducing the high cost and uncertainty of developing new medical treatments, and taking more steps to help patients and doctors use them effectively after they are approved by FDA.
We can take steps today to improve the development and use of medical technologies, and find creative policy solutions that both support innovation and make healthcare more affordable, particularly for those with limited means and great needs. There are many ways to do this, but above all, we need to increase value in the process of developing and using new medical technologies. To these ends, a key element of FDA's new strategic action plan is efficient risk management. In all of FDA's major policies and regulations, the Agency is seeking to use the best biomedical science, the best risk management science, and the best economic science to achieve its health policy goals as efficiently as possible.
The enormous growth in research investment has required the Agency to deal with more complex and innovative products in development than ever before. As discoveries made in the laboratory are flowing into the medical products consumers are using, it means that the Agency is challenged to upgrade its own science to keep pace with this new innovation and the growing sophistication of manufactures. As part of a new FDA initiative on improving medical innovation announced in January 2003, the FDA is taking specific steps to help foster more efficient innovation, especially in emerging areas or those of great medical need. The initiative has several elements that are described below.
Need for Performance Measures
One element of this plan is the development of "quality systems" for the Agency's review procedures. The idea is to build on FDA's professional staff expertise to identify and apply best management practices internally to the review processes. This includes using peer review programs coupled with more empirical data for drug and device reviewers to exchange ideas and use each other's experience to learn about best practices. A key part of this effort is developing performance measures that the Agency's experts believe are related to the goal of approving safe and effective treatments as efficiently as possible.
FDA is also working to develop new guidance documents that can bring more predictability to regulatory process. These are in a tradition of FDA documents that serve as roadmaps for drug and device developers, offering guidance on how to structure studies to prove that new treatments work. These new documents represent an enhanced effort to combine internal expertise with input from outside experts to make sure that are regulatory methods are up to date in important areas of technology development. Some of the guidance will focus specifically on diabetes, obesity, and cancer. Despite all the innovation that has already occurred, these are therapeutic areas that remain underserved by effective treatments and that have promising technologies under development today.
Developing New Guidance for New Areas
The Agency is also developing guidance in new areas of technology development, including pharmacogenomics, novel drug delivery systems, and cell and gene therapy. In each of these cases, the Agency expects to learn something from outside experts in the open process of developing them. For example, FDA is setting up a "research exemption" program for product developers as well as academic experts to share data on pharmacogenomic results, such as microarray studies, that may be useful for predicting clinical benefits and risks and thus reducing the costs of demonstrating safety and effectiveness. This kind of information can also be used to increase the value of a new medicine by allowing doctors to target drugs to patients most likely to derive a clinical benefit or least likely to suffer a rare side effect. The goal in all of these endeavors is to use the new regulatory standards to reduce the time and cost of product development and to ensure that the Agency's regulatory procedures are current at the same time. We hope this will lead to earlier and broader access to new treatments.
Rapid Access to Generic Drugs
Supporting the development of safe and effective new treatments is one of the most important ways that FDA can promote the public health. But when appropriate patents have expired, we need to facilitate broader access through lower-cost generic drug alternatives. Generic drug manufacturers produce medications that are just as safe and effective as their brand counterparts. Yet the prices of generics are generally much lower. A generic version of a $72 average brand-name prescription costs about $17. With more brand-name medications coming off patent - more than 200 of them in the next few years - and with ever-improving scientific knowledge and public awareness about the benefits of generic drugs, the health and economic benefits of using generic drugs are constantly growing.
Encouraging rapid and fair access to more affordable generic medications is one of FDA's major priorities. FDA is proposing new resources to enable us to implement major reforms in its generic drug programs to reduce the time it takes to get a generic drug approved. Right now, it takes well over a year and a half on average to approve a new generic medication and we think we can significantly improve. In addition, the Agency recently finalized a generic drug final rule that would expedite and increase access to more affordable generic drugs by limiting the ability of innovator drug companies to receive multiple extensions that delay entry of generic competition. This final rule is projected to save American consumers $35 billion dollars over the next 10 years. Furthermore, this rule makes changes to the patent listing process that are also designed to improve generic competition.
Revised Good Manufacturing Practices
Another application of the principle of efficient risk management to reduce medical costs and improved outcomes is in improving the way that medical products are manufactured. These guidelines are referred to as good manufacturing practices (GMPs), and these GMP regulations for drugs have not been updated in 25 years. Meanwhile, best practices in manufacturing technologies and methods have undergone significant progress over that time, particularly in other high-tech industries. For example, the semiconductor industry also has a very low tolerance for impurities and inaccuracies in production. When its production processes were lagging because of high costs and too many errors that industry helped invent the "six sigma" production methods. Through continuous quality improvement, those methods achieved enormous improvements in production cost and quality, and they have since been widely adopted in manufacturing industries.
But continuous quality improvement in manufacturing hasn't been the subject of as much attention in the pharmaceutical industry, even though many experts on manufacturing processes believe that large savings in production costs could be realized while maintaining very high standards for purity and accuracy. FDA wants to make sure that regulations are encouraging such progress, not standing in the way. The Agency is working on a program for developing new GMPs based on the latest science of risk management and quality assurance. The new standards would be designed to encourage cost-reducing and precision-enhancing innovation in manufacturing and technology, and to ensure that all three FDA medical centers use consistent and up-to-date methods, including inspectors specializing in particular types of production methods.
In addition to substantial savings in the development and manufacturing of safe and effective medical products, there are many more opportunities to increase the value of the medical products FDA regulates after they are approved and maximize their public health benefits. By making better information available to patients and doctors about the benefits and side effects of new medical technologies, and by taking other steps to help doctors and patients avoid errors and adverse events, people can realize more value from these products by making better decisions about when to utilize them for maximum advantage.
Prevention of Medical Errors
Approved medical products, while safe and effective when used as intended, can be involved in costly and potentially preventable adverse events, including medical errors. A November 1999 report of the Institute of Medicine (IOM), entitled "To Err Is Human: Building a Safer Health System," focused a great deal of attention on the issue of medical errors and patient safety. The report indicated that as many as 44,000 to 98,000 people die in hospitals each year as the result of medical errors. About 7,000 people per year are estimated to die from medication errors alone—about 16 percent more deaths than the number attributable to work-related injuries.viii
Preventable errors and complications involving prescription drugs alone are also responsible for billions of dollars in additional health care costs each year, in addition to all of the unnecessary suffering. The IOM report estimates that medical errors cost the Nation about $37.6 billion each year; about $17 billion of those costs are associated with preventable errors. About half of the expenditures for preventable medical errors are for direct health care costs. That's too much money that would be better spent on proper care.
FDA has a role in helping to avoid these costly errors by supporting the development and use of safer health care systems; systems that help health professionals avoid errors and deliver higher quality care. The majority of medical errors do not result from individual recklessness, the report says, but from basic flaws in the way the health system is organized. Stocking patient-care units in hospitals, for example, with certain full-strength drugs (even though they are toxic unless diluted) has resulted in deadly mistakes. And illegible writing in medical records has resulted in administration of a drug for which the patient has a known allergy.
To help mitigate these risks, earlier this year FDA proposed a universal bar coding system for prescription medications and blood products. Coupled with barcode readers and electronic medical records, bar codes on drugs are expected to reduce the rate of medication errors that occur at the stage of dispensing and administering medications by half or more. Bar codes can help make sure that the right patient gets the right medication in the right dose at the right time, and soon a standardized system of codes will be built in to all drug packaging. Based on the published relationships between hospital admissions and adverse drug events, FDA has estimated that of 372,000 preventable adverse drug events per year in hospitals, bar code identifiers on drug products could be expected to avoid about 22 percent of these events. Over 20 years, FDA expects more than 413,000 fewer adverse drug events because of bar coded products. The average annual benefit of avoiding these events is $3.9 billion dollars in patient pain and suffering and direct treatment costs.ix FDA's work on standards has another benefit. According to the hospital industry and many health care purchasers, standard bar codes will speed the adoption of electronic health information systems by hospitals and other healthcare organizations, because the standardized codes increase the payoff from having electronic systems.
Even with the best available data, drugs are sometimes found to have adverse effects that could not have been predicted or uncovered in any feasible clinical trial. Most of these subtle or rare problems, such as liver toxicities, that occur in a small number of people and most become apparent only after drugs have been used in real-world patient populations for some period of time. The Agency must have effective systems in place to detect such problems, so that preventable adverse events are identified, and better ways can be found to prevent these events.
As part of this effort, the Agency is working on developing information technology tools that will allow it to link into the electronic medical records of large healthcare institutions and organizations, and automatically scan medical records for combinations of new drugs and clinical endpoints such as blood test results that might contain harbingers of trouble. The idea is to use modern information technology to acquire information on associations between adverse events and use of a medical product that might warrant focused further investigation. FDA wants to have systems in place that allow us to be proactive in collecting this clinical information, rather than continuing to rely primarily on vigilant doctors and FDA's voluntary adverse event reporting systems.
Safety and Efficacy Studies for Approved Medical Products
More studies of the safety and effectiveness of medical products after they are approved can be very helpful for learning more about the risks and benefits of medications in special populations and can help guide more informed medical decisions. For example for a new cancer drug that recently gained accelerated approval, the National Cancer Institute is funding so-called
"Phase 4" studies to confirm clinical benefits and help assess longer-term risks. These efforts to use modern information systems and post-approval studies can add substantially to the body of knowledge about which patients are most and least likely to benefit from an approved treatment, in turn leading to higher-value treatment decisions.
Better Informed Consumers
FDA is also working to encourage more effective, high-value use of medical treatments by helping patients and health professionals get access to the latest and best information on risks and benefits. For all that improving medical technology can do, it is much less than people can do through their own choices to improve their health. From encouraging better guidance to patients in pharmacy labels, to clearer guidance on communicating risk and benefit information in direct to consumer advertising, to new enforcement initiatives against dietary supplement manufacturers who make health claims without scientific foundation, to food labeling that better discloses diet-disease information, FDA is undertaking new efforts to help consumers make better-informed decisions about how to use their health care dollars. In one recent example, FDA is working on a DailyMed program for physicians, so that a redesigned electronic product label that can be updated daily to include the most current information about a drug after they are already on the market. Only by facilitating access to complete, timely, and easily used information available to consumers and health professionals can FDA help to make sure that people are making the best decisions about their health based on the best available information.
Medical innovation is a difficult and complex process, but one that can bring great value to patients. This long and difficult process is also a delicate one that requires the right mix of incentives, safeguards, and effective regulation to make sure people can derive the maximum benefit from safe and effective new medical technologies. Only by adopting policies that protect the incentives to develop new drugs and medical devices, and reward cost-effective medical practice and the most high value use of new technology, will we continue to realize the full benefits of these innovations. As described in this testimony, at FDA, as Commissioner of Food and Drugs, I am working to implement numerous policies, initiatives, and regulatory improvements that reflect these critical needs in order to promote increased access to high quality, high value, safe and effective medical products, including drugs, biologics, devices and combinations of all three.
I appreciate the opportunity to provide this testimony and I would be pleased to respond to any questions.
i Measuring the Health of the United States Population", Brookings Papers on Economic Activity, Microeconomics, 1997, 217-272 (with Elizabeth Richardson).
ii Cutler, David M. and Mark McClellan. "Is technological change in medicine worth it?" Health Affairs; September/October 2001: 11-29.
Grabowski, H., J. Vernon, J.A. DiMasi. "Returns on research and development for 1990s new drug introductions."
In "The Cost and Value of New Medicines in An Era of Change." PharmacoEconomics 2002;20 (Suppl 3):11-29.
iii Lichtenberg, Frank R. Are the Benefits of Newer Drugs Worth Their Cost? Evidence From the 1996 MEPS,"reprinted from Health Affairs, Vol. 20, No. 5, September/October 2001.
Kleinke, J.D. "The Price of Progress: Prescription Drugs in the Health Care Market," reprinted from Health Affairs, Vol. 20, No. 5, September/October 2001.
Lichtenberg, Frank R. "The Effect of New Drugs on Mortality from Rare Diseases and HIV." NBER Working Paper W8677, December 2001.
iv DiMasi, J.A. "Uncertainty in drug development: approval success rates for new drugs" Chapter 20 in Clinical Trials and Tribulations, 2d Edition, revised and expanded. Cato AE Sutton L Cato A III, editors. New York: Marcel Dekker, 2002:361-77.
v DiMasi, J.A., Hansen, R.W., Grabowski, H.G. "The Price of Innovation: New Estimates of Drug Development Costs." Journal of Health Economics, 2003 Mar;22(2):151-85.
Kaitin KI, Ed. "Post-approval R&D raises total drug development costs to $897 million." Tufts Center for the Study of Drug Development Impact Report 2003 May/Jun;5(3)
vi Horrobin, David F. "Modern Biomedical Research: An Internally Self-Consistent Universe with Little Contact with Medical Reality?" Nature Drug Discovery; February 2003:151-154.
vii CDER 2002 Report to the Nation: "Improving Public Health through Human Drugs." May 13, 2003.
viii To Err Is Human: Building a Safer Health System. Institute of Medicine Press, 2000.
ix Bates, D.W., D.J. Cullen, N Laird, L.A. Peterson, S.D. Small, D Servi, et al. "Incidence of Adverse Drug Events and Potential Adverse Drug Events: Implications for Prevention. The Journal of the American Medical Association. July 5.1995.
Classen, D.C., S.L. Pestonik, R.S. Evans, J.F. Floyd, and J.P. Burke. 1997. "Adverse Drug Events in Hospitalized Patients: Excess Length of Stay, Extra Costs, and Attributable Mortality. The Journal of the American Medical Association. January 22/29.
Jha, A.K., G.J. Kuperman, J.M. Teich, L Leape, B Shea, E Rittenberg, et al. 1998. "Identifying Adverse Drug Events. The Journal of the American Medical Association. May.


text:
Is MTConnect "Priceless?"
"MTConnect opens a world of possibilities for automating and streamlining shop operations."
Related Topics:
"MTConnect: What's it going to cost me?" Among machine tool users, misconceptions about this data communications standard are clouding the answer to that question. Some shops have the false impression that all MTConnect-related products will be free as Internet downloads. Their interest in acquiring it, however, is easy to understand. MTConnect promises real value to end users and vendors alike.
This communications standard is designed to unlock the data generated by the computers or microprocessing systems running most of today's production equipment. Accessing this data and sharing it with other devices or software applications opens a world of possibilities for automating and streamlining shop operations. That is why developing a vendor-neutral, open-source and royalty-free standard, which specifies a digital format for capturing data and publishing it across a network, was a high priority. The initial version of the standard was introduced at IMTS 2008, where early adapters demonstrated "plug-and-play" connectivity among various pieces of equipment from multiple suppliers. It was a big hit at that show and again at IMTS 2010.
Apparently, what causes a little confusion is the standard's royalty-free status. This simply means that developers can use it without paying anyone to do so. No license fees are involved. In fact, the standard's source code and other useful support material can be freely downloaded at the web site (mtconnect.org) maintained by the MTConnect Institute, the not-for-profit organization set up to oversee the ongoing effort to extend and enhance this standard. By intent, no restrictions or obligations are imposed on developers or users who choose to implement it. So, if you develop an application or solution that uses MTConnect and decide to sell that as a product for profit, that's perfectly fine. If you decide to keep it just for your own use or give it away free, that's perfectly fine, too.
That's why some MTConnect-enabled applications, such as highly functional machine monitoring systems, are likely to require a licensing fee. Other related software programs may be free. For example, members of the MTConnect user community share many "adapters" and "agents" at no charge. These are the software programs that must be installed so that a device can translate internally-generated data to comply with the standard (the role of an adapter) or present it in a database that can be interfaced to network communications programs (the role of an agent). The availability of these programs promotes wider implementation of the standard, and ultimately creates a market for the pay-to-use applications built around this new data exchange capability.
When considering any MTConnect implementation, potential users will have to judge for themselves if the cost/benefit trade-off is worthwhile. No doubt, many of the applications will be deemed great bargains when evaluated against the productivity gains to be realized.
Editor PickEMO 2017: A Sneak Peek
EMO, the world's largest metalworking show will be back in Germany September 18-23 with the theme of "Connecting systems for intelligent production."


text:
|Home > Alejandra
♀ Alejandra
What does Alejandra mean?
Alejandra [ale-jan-dra]▼ as a girls' name has its root in Greek, and Alejandra means "man's defender". Alejandra is an alternate spelling of Alexandra (Greek): Latinate feminine respelling of Alexander.
VARIANT Alejandrina
ALTERNATIVE FORMS VIA ALEXANDRA Alandra, Alejanda, Aleksandra, Alesandare, Alesandere, Alessanda, Alessandra▲, Alessandre, Alexanda, Alexander, Alexanderia, Alexandre, Alexandrea▼, Alexandrena, Alexandria, Alexandrina, Alexsandra, Alixandra, Alixandria, Allejandra, Allejandrina, Allessandra, Allexandra, AlyxandraCREATIVE FORMS
(male) MIDDLE NAME PAIRINGS
Alejandra Peyton (A.P.), ..
How popular is Alejandra?
Alejandra is a very prominent first name for females (#797 out of 4276, Top 19%) and a slightly less prominent last name for all people (#138741 out of 150436, Top 92%). (2000 U.S. CENSUS)
Alejandra was first listed in 1960-1969 and reached its top rank of #147 in the U.S. in the year 1993, and is presently at #451. (TOP 2000 NAMES, 2015)
Which version is better?with its source form and related girl names. Popular related forms of Alejandra (#451 LAST YEAR) are Alexandra (#101), Alexandria (#213), Alessandra (#276), Aleksandra (#1828), Alexsandra, Alexander and Alexandrea. Other forms, like Alesandare, are uncommon. Adoption of these relations of Alejandra was common 2 decades ago (USAGE OF 1.19%) and is now much less (USAGE 0.41%, 65.4% LESS), with versions like Alexandra going out of style. Alexandra is more familiar than the rest, although Alessandra appears to be gaining popularity too.
Similar NamesRecommended names are Alacinda (see Alcinda), Alcinda, Aleana, Aleanor, Alessandrina, Alexandreana, Alexandrene, Alexandretta, Alexandrine, Alexanna, Alexanne, Alexena, Alexina, Alicinda (see Alcinda), Alissandre, Allcinda (see Alcinda), Allexandrina, Alondra▼, Alyssandra, Deandra, Deeandra, Dejanira, Delandra, Eleanora, Keandra, Leandra, Leiandra and Lexandra. These names tend to be less frequently used than Alejandra.See names in meaning and etymology.


text:
Longtime Brooklyn Mayor Dead
(Brooklyn, OH) - A political icon in Cuyahoga County for generations has passed away. John Coyne, 97, served as the mayor of Brooklyn for 51 years. His first term commencing in 1948.
Coyne's is the longest serving mayor in the country's history for consecutive terms.
Under Coyne's leadership, Brooklyn became the first city in the United States to adopt motor vehicle laws which are now widely enforced: Mandatory seat belt use and a ban on the use of a cellphone while driving.
He was a influential voice in the local democratic party for many years.
Photo credit: Busch Funeral Services
Get breaking news sent to your mobile phone.Text "news" to 21095.


text:
Women's White Kiel James Patrick Pearl Bracelet
Kiel James Patrick for Brooks Brothers. Pearl bracelet hand-knotted 10 mm glass pearls with anchor clasp with BB#5 stripe ribbon end. Anchor clasp has Brooks Brothers and KJP logos. Made in the USA.MEASUREMENT. XS: 6.5". S: 7" (Most Popular Women's Size). M: 7.5" (Most Popular Men's Size). L: 8". XL: 8.5". Color: white


text:
Home > Documents
|Approved by the Mānoa Faculty Senate
53 in support: 9 opposed
- 5/15/2015
Committee on Administration and Budget
Spring 2015 Report: CAB reviewed the reorganization proposal and brought a resolution to the Senate recommending rejection. SEC addressed part of this over Summer 2014 with a possibility that a revised reorganization may come from CSS to CAB again but it has not happened during this academic year.
- 1/5/2015
Committee on Administration and Budget
Fall 2014 Report: CAB reviewed the reorganization proposal and brought a resolution to the Senate recommending rejection. SEC addressed part of this over the summer with a possibility that a revised reorganization may come from CSS to CAB again.
- 6/9/2014
Senate Executive Committee
Senate Executive Committee Motion to Approve Revised Reorganization Proposal for the College of Social Sciences [Passed; unanimous]
- 6/2/2014
SEC Presentation by Robert Bley-Vroman, Dean (on behalf of A&S Council of Deans)
CSS Presentation to the SEC
CNS Advising Proposal
Vision for A&H LLL Center for Humanities Advising
- 5/30/2014
College of Social Sciences
Action Memo
Executive Summary
Task Force Report
- 5/14/2014
College of Social Sciences
Student Services Proposal - Beyond Advising: The College of Social Sciences HUB
- 5/7/2014
Manoa Faculty Senate
Resolution Recommending Rejection of the College of Social Sciences Reorganization [Passed; 53:9]
- 4/7/2014
Senate Executive Committee
Referral: Committee on Administration and Budget.
- 3/24/2014
Vice Chancellor for Administration, Finance and Operations
Request: Reorganization Proposal for College of Social Sciences; direct questions to Denise Eby Konan (firstname.lastname@example.com); review by May 8, 2014.
[PDF] (Transmittal)
[PDF] [DOC] (Resolution)
[PDF] [DOC] (Checklist)
Resolution Recommending Rejection of the College of Social Sciences Reorganization
Whereas, The proposed reorganization of the College of Social Sciences (CSS) mixes two different and separable proposals for an Office of Student Academic Services (OSAS) and a Global Studies Center (GSC), and
Whereas, The CSS reorganization for OSAS and GSC is advertised as "no additional funds are required" or "cost neutral," yet e.g. in the OSAS section it states "However, additional funds will be required to fund an IT Specialist, Assistant Specialist in Hawaiian Advancement and additional advisors, clerical support and graduate assistants," at an additional cost of $461,000, and
Whereas, No justification is given for the proposed OSAS IT Specialist, Assistant Specialist in Hawaiian Advancement and additional advisors and support staff, which is only a partial list of positions required, and
Whereas, Appropriations were requested by the CSS for $500K as part of the Governor's Message 241(GM241) package for the GSC, a proposed new academic department within the Dean's Office with future plans for BA and MA programs in Global Studies, but it did not receive funding, and
Whereas, No indication is given as to where additional funding and positions will come from for both OSAS and GSC, and
Whereas, Internal allocations to fund these new initiatives may result in further delaying hires for tenure track faculty and/or APT positions that were left vacant by retirements, deaths and resignations, which is already of major concern within the CSS, and therefore the economic viability of the proposal is questioned, and
Whereas, Reducing or eliminating faculty replacements will impact course offerings required for fulfilling degree requirements on a timely schedule unless funding from sources external to the College are secured, and furthermore that reduced instructional resources will ultimately affect student graduation rates and negatively impact the Hawaiʻi Graduation Initiative, a UH system-wide strategic initiative that focuses on increasing the number of educated citizens within the State, and
Whereas, "Center" designation requested for GSC should follow the "Center" approval process, per Executive Policy E5.215-Establishment and Review of Centers, which is governed by the Board of Regents, and
Whereas, An academic program should not be located directly in the Dean's office (and there is no clarity in the proposal between the administrative and academic parts of the GSC), and
Whereas, The GSC appears to duplicate some of the functions found in the Study Abroad Center, School of Pacific and Asian Studies (especially its MA in Pacific Asian Studies Program), and potentially more, and
Whereas, The Colleges of Arts and Sciences (CAS) have eliminated the global perspective breadth and depth requirement as a whole, the College continues to investigate how to encourage study abroad for all CSS students (approx. 1700 undergraduates) as part of each student's path of study, and
Whereas, The SEC appointed Advisory Council should be consulted since official University sponsored study abroad programs are not permitted outside of UHM Study Abroad Center oversight/purview (details at http://www.studyabroad.org/about/principles/) and furthermore, study abroad liability issues must be addressed per CAPP report by Dr. Sarita Rai to UHM SEC Chair David Ross, dated 12-14-10, re "Report on Risk Management Sponsored International Study, Research and Training Involving UHM Students, Faculty and Staff" and Executive Policy E8.207 to limit University liability, and
Whereas, The reorganization proposal was not brought to the Social Sciences Chairs and Directors meeting for discussion and full consultation including programmatic and budgetary impacts to the existing CSS departments, and
Whereas, The larger picture of the reorganization of Arts and Sciences Advising, with two (2) advisors each going to the College of Social Sciences and the College of Natural Sciences, should be addressed at the same time as the OSAS, therefore, be it
Resolved, That the Manoa Faculty Senate strongly recommends to the Chancellor and the Vice-Chancellors for Academic Affairs and for Administration, Finance and Operations that the proposed reorganization of the College of Social Sciences be rejected and that the College of Social Sciences be asked to prepare two separate and new proposals addressing all the above concerns to be reviewed by the Senate Executive Committee to ensure that the concerns have been met.


text:
I got my first injections the first week of June in the nabiial folds and a little around the mouth., It is now 2 months later and it seems to have dissipated and perhaps, drifted away from the groove or wrinkle to the fold themselves, exaggerating them and what looks to be a small bump that looks to be part of a muscle or tendon? It's bascially this. I feel I look worse than I did before hand, which is maddening, considering the cost. I have lost about 28 lbs in th elast year and iam 47. Thanks
Resyalyne Only Lasted 2 Months. Can It Drift from Injection Site and Make You Look Worse?
Doctor Answers 9
Restylane problems
Restylane, although usually lasts up to 6 months, is some people may last less. It does not migrate, however (!), when injected into a a very active area the constant movement, such as in the nasolabial fold, can "push" the substance away from the groove into the fold behind it.
Restylane results
Disappointing Results with Restyalne
I'm sorry you're disappointed with the result of your Restylane injection. Many patients have had similar experiences with fillers like Restylane. They often do not last as long as expected and may result in some lumpiness or irregularity depending on the skill or technique of the injector. Lumps or discoloration can be readily corrected by injecting a solution that dissolves the filler immediately. I agree with Dr. Schwartz in that Radiesse often provides better correction of the nasal labial folds since it adds more volume to the deeper tissues and stimulates collagen as well. The longevity of Radiesse compared to Restylane is typically much longer and many patients prefer this filler. It is very important when getting facial fillers, particularly long-lasting fillers like Radiesse, that you go to a very experienced provider.
Good luck to you.
You might also like...
Best fillers for the nasolabial folds
With your amount of weight loss I suspect you need a more robust filler such as Radiesse for your nasolabial folds. Radiesse has been proven to be much more effective than hyaluronic acid fillers like Restylane for treatment of the nasolabial folds. The problem you are describing is most likely due to the use of a more superficial "wrinkle filler" like Restylane in this area instead of a "volume filler". Several years ago a study was done where Radiesse was injected into one nasolabial fold and, in the same patient, fillers containing hyaluronic acid such as Restylane were injected onto the other nasolabial fold. The majority of patients and observers picked the Radiesse side as more natural looking. This is because of the difference between "stimulatory" fillers and "wrinkle" fillers. Radiesse is injected more deeply beneath the skin and will generate more volume to create a much better lifting effect with a much more natural look. It works by stimulating your skin to produce more collagen, which is why it is so effective, and gives longer-lasting results too.
Learn more: http://www.dorsetstreetdermatology.com/cosmetic-dermatology/radiesse/
The product is still there.
Please go back to your injector and look at before and after pictures. If no before pictures were taken, then you are getting service in the wrong place.
Restylene for smile lines
Restylene is one of the better fillers for smile lines and wrinkles around the mouth area. if you feel like it has disappeared after 2 months Im not surprised as in some patients it can dissolve sooner. especially if they are on a restricted dietary lifestyle. I would recommend that u see your doctor who did the injections for you and follow up on their advice
Restylane and migration
You should consider posting photo's to show the area of concern, pre and post-treatment with filler. The product typically will last anywhere from 6 months to a year, dependent upon placement and injection technique.
Unhappy with the result of Restylane treatment
In general, fillers help volumize the face. Sometimes when one loses weight, volume can be lost on the face as well and can have an effect on one's appearance. It is possible that this may be confused with the filler losing effect. The filler will not migrate away from the injection site. If lumps or bumps are present, hylauronidase can be used to dissolve any filler that exists in these areas. This will allow you to look the way you did prior to having the injections. From here, I wold recommend following up with your physician who performed the injections. He/she may be able to tell what is going on and provide a possible solution for your issue. Thank you and I hope this helps!
Learn more: http://www.spaldingplasticsurgery.com/fillers-and-injectable/restylane/
Restyalne is ideal around the nasolabial folds and mouth and cannot drift
It sounds like your weight lost may be responsible for your face changing in some way. If there is a bump or lump that is there you should return to your injecting physician and let them evaluate if that is from Restylane. It sounds like you lost volume or fat in your face with the weight loss and may need a thicker injection like Juvederm.
Learn more: http://www.michelegreenmd.com/restylane
These answers are for educational purposes and should not be relied upon as a substitute for medical advice you may receive from your physician. If you have a medical emergency, please call 911. These answers do not constitute or initiate a patient/doctor relationship.


text: Fair enough. I was using the samples provided in the documentation. I think those should be updated then. I will try things out with the samples in the source. Brian Andrus ITACS/Research Computing Naval Postgraduate School Monterey, California voice: 831-656-6238 -----Original Message----- From: torqueusers-bounces at supercluster.org [mailto:torqueusers-bounces at supercluster.org] On Behalf Of Al Taufer Sent: Tuesday, March 15, 2011 12:23 PM To: Torque Users Mailing List Subject: Re: [torqueusers] Enabling BLCR on Torque roll (problemswith "qhold") I believe the scripts in torque/contrib/blcr both work. You may need to change the PATH depending upon your installation. These scripts also document what parameters should be passed in and what the order is. Al Taufer Adaptive Computing ----- Original Message ----- > Ricardo, > > I have started working on this too. > A couple things I have seen so far: > > 1) The sample blcr_checkpoint_script has some issues (it is missing a > comma on line 36 and $depth is not defined on line 21) > > 2) The # of arguments passed to the script by pbs_mom is 8. If the > script does not receive exactly 7, it is not happy. > > 3) What arguments are passed and in what order does not seem to be > documented and it _appears_ that the sample script is expecting > something other than what is being passed (eg: it is trying to 'cd' to > the headnode name) > > > So my question to the list: > > Does anyone know the arguments and order that pbs_mom passes to the > checkpoint script? > Or > Does anyone have a working checkpoint script? > > > Brian Andrus > ITACS/Research Computing > Naval Postgraduate School > Monterey, California > voice: 831-656-6238 > > -----Original Message----- > From: torqueusers-bounces at supercluster.org > [mailto:torqueusers-bounces at supercluster.org] On Behalf Of Ricardo > Alves > Sent: Tuesday, March 15, 2011 11:28 AM > To: torqueusers at supercluster.org > Subject: [torqueusers] Enabling BLCR on Torque roll (problems with > "qhold") > > Hi, > > Torque was compiled adding the "--enable-unixsockets=no --enable-blcr" > line to the ./configure command (as it says on the torque tutorial - > http://www.clusterresources.com/torquedocs21/2.6jobcheckpoint.shtml). > > Both scripts are present in the mom_priv directory with execution > privileges and the paths are in the mom_priv/config (the config file > is > attached to this mail) > > thank you. > _______________________________________________ > torqueusers mailing list > torqueusers at supercluster.org > http://www.supercluster.org/mailman/listinfo/torqueusers _______________________________________________ torqueusers mailing list torqueusers at supercluster.org http://www.supercluster.org/mailman/listinfo/torqueusers


text:
Cars > Events > Lone Star Shootout
Contact Information
- D & M Promotions, Inc
- (321) 243-5231
Comments on this Event
Log in to post comments.
Read comments on this event (0)
No comments have been posted on this event.
About Lone Star Shootout
Public Gates Opens 9am
ALL MOPAR Bracket Racing ... Super Pro, Pro, Sportsman, Trucks, Slant Six and Vipers
Quick 16 Racing
Mopar Action Street Car Shootout
Nostalgia Super Stock/Nostalgia Muscle Cars
Manufacturers Midway & Swap Meet
All Mopar Car/Truck Show
Date and Time
Sat Oct 21, 2006 – Sun Oct 22, 2006
8:00 am – 7:59 pm (CDT)
Location and MapHouston Raceway Park
2525 F.M. 565 South
Baytown, TX 77520
United States


text:
Description: Use it to generate infrared light.
- Select 2 format : Continuous Active all time apply logic "HIGH". Use with Infrared Detector to measure the infrared light density and use to proximity switch.
- Frequency This format will be modulate 38kHz carrier frequency with infrared light. Use with 38kHz Infrared Receiver module.
0.02 kg
3.0 months


text:
Tigers 4, Blue Jays 1: Doug Fister tossed eight strong innings and Jhonny Peralta provided the offense with a pair of home runs as visiting Detroit salvaged the final contest of a three-game series, snapping Toronto's three-game win streak.
Fister (5-7) struck out nine - one shy of his season high - and scattered seven hits for his fourth consecutive quality start, and Jose Valverde struck out two in a perfect ninth for his 20th save.
Brett Cecil (2-4) kept up the solid pitching that helped Toronto claim the first two games of the series, going 6 2/3 innings in his longest outing of the year. He struck out seven and allowed just four hits.
Cecil's only major mistake was a 3-2 breaking ball that Peralta belted into the bullpen beyond the left-field wall for a three-run homer in the second. Peralta added his eighth homer in the ninth against Joel Carreno, driving a 1-2 curveball to left-center.
The Blue Jays' only run came in the first, when Rajai Davis led off the inning with a broken-bat single, stole second and took third on a throwing error before scoring on a Colby Rasmus groundout.
The Tigers moved within 1.5 games of the American League Central-leading Chicago White Sox, who lost at Texas on Sunday night.
GAME NOTEBOOK: The Tigers avoided their first sweep in Toronto since Sept. 5-7, 2003. … Fister has recorded eight or more strikeouts in three of his last four outings and four times in all this season. … Peralta has seven two-homer games in his career, including three with the Tigers. This was his first since Aug. 15, 2010. … Blue Jays 3B Brett Lawrie went 0-for-3 to snap his hit streak at seven games, but SS Yunel Escobar went 1-for-3 to extend his streak to seven games.


text:
Jones will sit down with new chairman Peter Ridsdale, who took over from Sam Hammam last week, to discuss if he will also have transfer money to spend.
"All the things I didn't know will be answered in a few days," Jones said.
"But my job hasn't changed. Last year when we didn't have money it didn't mean we stopped looking at players."
The new investment backing Ridsdale is what he says are "two or three" London-based financial institutions that specialise in hedge funds.
While full financial details are still to emerge, it is expected to reduce some of Cardiff City's £24m debt - perhaps by as much as £9m - while also providing funds to strengthen the playing squad in the January transfer window.
The club's first team and youth Academy players train at the Cardiff University playing fields in Treforest, but these facilities can be limited by the weather.
Jones is eager to press ahead with securing modern private training facilities and expects good news soon.
"Peter had meetings the other day and once all that is signed and sealed that will be announced and hopefully we'll be using it in June or July," Jones added.
Hammam's reign has seen plans for a new stadium for the club advanced and the team sit proudly at the top of the Championship.
Jones is grateful to Hammam for bringing him to the club and for his past efforts, but the former Wolves and Southampton boss is looking to the future.
"I think the decision Sam has made is the right one and he admits that," Jones said.
"It's the saddest saying there is: 'the king is dead, long live the king' and everybody does move on, but Cardiff City can go forward now.
"The good thing is that it's not like someone coming in from outside who doesn't know the football club.
"Peter's taken over so that keeps the continuity going and we can all deliver what everyone wants.
"I got on well with Sam, he brought me here with Peter, he was a football person and the things that he's done have been fantastic for the club.
"Along the way Sam will say that he made mistakes, but everyone does that anyway."


text:
The best place to find jQuery plugins !
Welcome on myjqueryplugins,
the best jquery plugins library !
Create an account.
Sign up in 30 seconds !
Add your jQuery plugin.
Connect it with GitHub and create your plugin Homepage.
Make known your plugin to the community or link it to your own website !


text:
O'Reilly on Rosie O'Donnell: a "blithering fool" who is "full of you-know-what"
Research ››› ››› JULIE MILLICAN
Bill O'Reilly attacked Rosie O'Donnell for stating on September 22 that, despite O'Reilly's claims to the contrary, O'Reilly wasn't "that working class" while growing up because "[h]e went to the [high] school where all the rich Catholic kids went." O'Reilly called O'Donnell a "blithering fool" and announced that he would "tell her that to her face" during his upcoming appearance on ABC's The View, which O'Donnell co-hosts.
During the September 25 editions of both Westwood One's The Radio Factor and Fox News' The O'Reilly Factor, host Bill O'Reilly attacked Rosie O'Donnell, co-host of ABC's The View, for stating on September 22 that, despite O'Reilly's claims to the contrary, O'Reilly wasn't "that working class" while growing up because "[h]e went to the [high] school where all the rich Catholic kids went." On October 15, O'Reilly reportedly will appear as a guest on The View to promote his new book Culture Warrior (Random House, September 2006).
On his radio show, O'Reilly called O'Donnell a "blithering fool" and announced that he would "tell her that to her face" during his upcoming appearance on The View. O'Reilly said that O'Donnell, "[radio talk show host] Al Franken and all these other assassins are, you know, full of you-know-what, four-letter word."
Later that evening on The O'Reilly Factor, O'Reilly pointed to O'Donnell's comments as evidence of the "S-P [O'Reilly's abbreviation for "secular-progressives"] smear machine" being "cranked up" over Culture Warrior. O'Reilly declared that the "smear-O'Reilly machine" was attacking his book and declaring that "O'Reilly lies," adding that O'Donnell was the "number one" person who "buys into this propaganda." Continuing, he announced that on his October 17 appearance on The View, "I'm going to have Rosie read page 92 of Culture Warrior aloud." Page 92 of his book is near the end of his chapter on "The Battle for Christmas," and discusses how the alleged "war on Christmas" has started to spread to Easter. As purported proof, O'Reilly, on this particular page, pointed to an incident in St. Paul, Minnesota, in which a secretary was asked to remove her Easter decorations from her desk. It appears that O'Reilly might have intended to refer O'Donnell to page 96, where, as Media Matters for America has previously noted, O'Reilly attacks Franken for citing a Washington Post article, which quoted O'Reilly's mother, to assert that O'Reilly grew up in a wealthier community than he claims he did. On page 97, O'Reilly prints what he said was the deed to his parents' house to prove Franken was "deliberate[ly]" lying about O'Reilly's upbringing.
As Media Matters has documented, O'Reilly's book is rife with factual misrepresentations and inaccuracies, as well as unsubstantiated personal criticism and ad hominem attacks. While O'Donnell is not singled out in O'Reilly's book, O'Reilly recently criticized O'Donnell for her September 12 remarks on The View, in which, during a discussion about President Bush's September 11 address to the nation and the fight against terrorism, she asserted that "radical Christianity is just as threatening as radical Islam in a country like America where we have a separation of church and state." For instance, on the September 14 edition of his nationally syndicated radio show, O'Reilly declared O'Donnell to be "hyper-partisan[]"; asked "What planet are you living on, madam?" and stated, "Rosie O'Donnell is angry because she's gay, she wants to be married, she wants to adopt people and she perceives that the ones preventing her from doing that are evangelical Christians." O'Reilly repeated this claim during the September 20 edition of The Radio Factor, stating, "she's resentful toward the Christian right because they don't wanna give gays adoptions privileges and they don't want gays to get married. And she, her, that's her life now. She's a gay advocate " O'Donnell made no mention of gay rights while discussing terrorism on The View's September 12 broadcast.
Also on the September 14 edition of The Radio Factor, O'Reilly took umbrage at O'Donnell's statement that "[a]s a result" of the September 11, 2001, terrorist attacks "and the killing of nearly 3,000 innocent people, we invaded two countries and killed innocent people in their countries." O'Reilly responded by saying he was "gonna ask" O'Donnell "about Afghanistan" during his appearance on The View because "war is you destroy the enemy, and when you destroy the enemy, innocent people get killed, and that is what war is." O'Reilly asserted that O'Donnell's "argument is easily shot down" because "radical Christianity, whatever that may be," is "not on a jihad to kill anybody." O'Reilly further declared that it was "insane" that audience members applauded O'Donnell's remarks, and concluded: "[Y]ou're just sitting there and you're looking at the woman, and ... looking at Barbara Walters going, 'Boy, I don't know whether I did the right thing by hiring her.' "
On the September 15 broadcast of The Radio Factor, O'Reilly agreed with a caller's assertion "that 60 years ago, there'd be millions of...Jews pulled out of the ovens at Auschwitz that would probably disagree with" O'Donnell's anti-war statements. O'Reilly also called O'Donnell's remarks "absurd," anointed O'Donnell an "S-P warrior," used O'Donnell's comments as an opportunity to promote the Culture Warrior, and announced that "you can't get a better window on the culture war in this country" than by listening to O'Donnell's remarks.
From the September 12 edition of ABC's The View, which also featured co-hosts Joy Behar, Elisabeth Hasselbeck, and Barbara Walters:
HASSELBECK: Because we were attacked five years ago. So I do --
O'DONNELL: Wait a second. We were attacked, not by a nation. And as a result of the attack and the killing of nearly 3,000 innocent people, we invaded two countries and killed innocent people in their countries.
HASSELBECK: But do you understand that that the belief funding those attacks, OK? That is widespread. And if you take radical Islam and you want to talk about what's going on there -- you have to -- you have to --
O'DONNELL: And Just one second. Radical Christianity is just as threatening as radical Islam in a country like America --
HASSELBECK: Anything -- are we --
O'DONNELL: -- where we have a separation of church and state. We're a democracy.
HASSELBECK: We're not -- we're not bombing ourselves here in the country. We are being attacked.
O'DONNELL: Yeah, but we are bombing innocent people in other countries. True or false?
BEHAR: But -- but -- but Christians are not threatening to kill us. There's that difference.
HASSELBECK: No, we're talking about our safety here. And if you -- This is a --
BEHAR: This group is threatening to kill us.
HASSELBECK: This is a terrorist group.
O'DONNELL: Well, Iran never threatened to kill us, and Iraq -- Iran is -- is a danger.
HASSELBECK: Yes.
O'DONNELL: Iraq and Afghanistan never threatened to kill us. Ever.
BEHAR: Well, they're building their nuclear weaponry in Iran --
HASSELBECK: Don't you feel that -- don't you feel that though this extreme terrorism in other countries -- we're not isolated here in the United States of America. That -- protecting our -- protecting our borders and making sure that the world is a safer place and a more peaceful place does affect our safety here.
O'DONNELL: But you'll never bring peace at the hands of war.
HASSELBECK: I disagree with that.
O'DONNELL: As a species, we have to rise above this.
HASSELBECK: But I -- we have --
BEHAR: John Miller, who's the -- who's in charge of homeland security in Los Angeles now --
O'DONELL: Yeah.
WALTERS: No, he's not, he's the assistant director of the FBI.
O'DONNELL: What's his job?
WALTERS: I think he was my partner on 20/20 --
BEHAR: You remember, he was saying that we have thwarted several attacks already in this country. That means that they are here trying. That means that we need to guard the ports.
O'DONNELL: The people who want us to be afraid are telling us that we should be even more afraid because we could have been worse off if it wasn't for them.
HASSELBECK: What a second. What about August? We just completely -- we dissipated --
O'DONNELL: We foiled --
BEHAR: It's an election year, let's not forget that.
HASSELBECK: We foiled an attack that was headed here --
O'DONNELL: Well, we didn't foil it.
HASSELBECK: -- you don't believe it.
WALTERS: Ladies and gentlemen, welcome to The View!
O'DONNELL: Well, the British -- wait --
BEHAR: This is it! This is The View!
O'DONNELL: The British CIA foiled it. We did not foil it. I don't think the American government can take credit for what the British government did.
HASSELBECK: You don't even want to know what they're foiling out there, because that would scare everybody to death. You need to have a little more faith in the system.
O'DONNELL: But they're scaring you enough already. They're scaring --
BEHAR: Do you feel safe? Do you feel safe? I don't. In New York City? I don't.
HASSELBECK: I'll tell you, I don't think anyone on September 11th in New York City felt safe yesterday. Today, I woke up and I realized, you know what, emotionally, I felt very -- I did feel threatened yesterday. I've come to that stage.
BEHAR: Yeah, you made that kick yesterday.
HASSELBECK: I did. I did.
BEHAR: Yeah.
HASSELBECK: I woke up today and thought about it on an intellectual level. We haven't had an attack in five years.
O'DONNELL: But do you know that --
WALTERS: But do you feel safe?
HASSELBECK: We are doing more to protect the borders.
WALTERS: Do you feel safe today?
HASSELBECK: I feel more safe -- I do feel as though we're on the offense against these extremists.
O'DONNELL: But let me ask [inaudible] one thing before we --
WALTERS: How can you feel totally safe --
O'DONNELL: I'm supposed to be moderating, and they're giving me the wrap card.
WALTERS: No, no, you can let us go. One more thing.
O"DONNELL: OK. Keep going.
BEHAR: Barbara has to say something. Go ahead, Barbara.
O'DONNELL: Go.
WALTERS: We are told it's not if but when. So none of us can really feel safe in that sense.
HASSELBECK: Yeah.
O'DONNELL: Right, but in life, you have two choices always -- faith or fear. A government should lead by faith, never by fear.
HASSELBECK: I think we are leading by faith.
BEHAR: How about rational -- how about rationality? What happened to that?
O'DONNELL: Faith is not Christianity -- faith in humanity; faith in equality; and faith in free giveaways, because frankly, that's what I think TV is really all about.
From the September 14 edition of Westwood One's The Radio Factor:
O'REILLY: Yeah, it does. You know, listen, I'm probably one of the top five most influential commentators in the world right now. My voice is heard by tens of millions of people. But I can't get through to the hyper-partisans.
I'm gonna give you another example of hyper-partisanship. You got that Rosie O'Donnell byte cued up? All right. Here's another -- look, I can only persuade reasonable people. I can't persuade those who are -- not insane, but so hyper-partisan they're never gonna change their mind. Roll Rosie O'Donnell.
O'REILLY: OK. So Rosie O'Donnell basically says two things. Number one: Radical Christianity is just as dangerous as radical Islam. And of course, that argument is easily shot down by -- look, radical Christianity, whatever that may be, evangelicals or whatever, they're not on a jihad to kill anybody. OK? That, that's -- that blows that argument right out of the water. And secondly, if Rosie O'Donnell thinks that invading Afghanistan was wrong, where the Al Qaeda had training camps to kill 3,000 Americans, then the argument pretty much ceases.
Now, I'm going on The View in a couple of weeks to promote Culture Warrior. I'm gonna ask Rosie O'Donnell about Afghanistan. You know, you're bombing innocent people. Well, by that measure we couldn't have attacked Germany or Japan. We bombed innocent civilians in both of those countries, Ms. O'Donnell. I mean, what planet are you living on, madam? You know, war is you destroy the enemy, and when you destroy the enemy, innocent people get killed, and that is what war is. And we didn't declare this war on terror, we were attacked. But this hyper-partisanship goes beyond reason. It's not reasonable. It's emotional.
Let's go to Cutchogue, Long Island. John, what say you?
CALLER: Hi, Mr. O'Reilly. How you doing?
O'REILLY: Good.
CALLER: Good. I have to tell you, I just listened to the -- the thing you had on with Arianna Huffington. And what's scary is she's not alone.
O'REILLY: No.
CALLER: She's not even close to being alone.
O'REILLY: Nope.
CALLER: There's millions of them. I went to a show last night, I went to a concert in Madison Square Garden, a Roger Waters show. Twenty thousand people in there, and I left in the middle of it. Halfway through the show I had to walk out because all of a sudden, there -- I was bombarded with graphics and everything calling the president stupid, calling [British Prime Minister] Tony Blair a lapdog. I mean -- it was just, it was out of control.
O'REILLY: Yeah. And -- and -- and --
CALLER: You know, the right-wing cult, the religious right --
O'REILLY: Yeah. Neil Young, Neil Young has done that all throughout his concert tour with Crosby, Stills and Nash this summer. It's not only out of control, it's offensive. It's offensive, and it's demeaning to somebody like you who goes in and pays good money to hear entertainment, and you get stuff rammed down your throat by people who don't know what they're talking about.
But here -- you're right about the millions of people. Did you hear the people applaud when Rosie O'Donnell said that radical Christianity is just as dangerous as radical Islam? I mean, it's insane. There are no radical Christian countries. There is no inquisition anymore in -- in the world. And it's just, you're just sitting there and you're looking at the woman, and you're -- and I'm -- And I'm looking at Barbara Walters going, "Boy, I don't know whether I did the right thing by hiring her." You see? Because once you get into that zone, it's -- it's almost impossible to get out of the zone. See once you define yourself that way, that radical, you can't come back.
CALLER: Bill, when Rosie O'Donnell compares radical Christianity to radical Islam, I think she's missing the most important point: Christ is probably the most radical Christian there was, and he laid down his life for others and he said there's no greater love than any man can have than to lay down his life for a brother. That's exactly the opposite of what Islamic fascists are. They're -- they're to take other people's lives --
O'REILLY: Yeah. But you know what's going on here. Rosie O'Donnell is angry because she's gay, she wants to be married, she wants to adopt people, and she perceives that the ones preventing her from doing that are evangelical Christians. So it's -- she's coming at it from solely that point of view. And I understand that. I mean, that's why she doesn't like radical Christians, as she calls them.
You know, O'Donnell and I were -- are from the same area on Long Island, Irish Catholic homes, you know, the same thing. Yet she went one way, I went another way. Is she a bad person? I don't think she is. But, again, she's a hyper-partisan, she looks at the issues through her prism, and her prism is these radical Christians, as she calls them, are preventing me from doing what I want. Therefore, they're as bad as the radical Islamists. You know, I'm sitting there going, "This is crazy," and all of you know it is. I don't have one call on the board saying this is true. The best they can do is, well, some nuts blew up an abortion clinic. That's the best they can do, you know, the -- the O'Donnell side.
From the September 15 edition of Westwood One's The Radio Factor:
CALLER: Bill, Hey, Bill. It's good to talk to ya. Yesterday, Rosie O'Donnell made a statement. She said peace never results from war. Now I hate war, I wish it never had to happen. But I'm willing to bet that 60 years ago, there'd be millions of Britons, French and especially the Jews pulled out of the ovens at Auschwitz that would probably disagree with that.
O'REILLY: Of course. I mean, that's an absurd statement. She also said that we were wrong to invade Afghanistan after 9-11. But, look, she's an American, and she's entitled to these opinions. We shouldn't hate her, but she should be challenged. Look, I'm going on The View in a couple of weeks to promote Culture Warrior. I'm coming in. Here I come.
Now, I got a few questions for Ms. O'Donnell. I got -- you know what I'm talking about? It's gonna be a very lively program. Am I gonna be mean to her? No. I'm gonna be very, very matter-of-fact. So, look, you know people in your own lives, your friends, some of them, are just nutty. You know, you just, you look at them, you roll your eyes. What else can you do?
CALLER: All right. My, my comment is to Ms. Rosie O'Donnell --
O'REILLY: Right.
CALLER: -- saying that radical Christianity has done so much damage. In fact, if you look at what the liberal godless theology has done to families in this society, there has been more damage in the last 40 years adopting their hedonistic, no values toward anything, especially human sexuality. We know that marriage is protective. We know that the number one group trapped in poverty are the ones choosing to have, you know, hedonistic, out-of, out of --
O'REILLY: But this is -- what you're talking about, what you're talking about, [caller], is the culture war.
CALLER: Yes it -- that's what I'm talking about -- So we have to document --
O'REILLY: Okay. Rosie O'Donnell -- yeah -- Rosie O'Donnell is a secular progressive, and you are a traditionalist. You're gonna love my book, Laura. In fact, send [caller] a galley of Culture Warrior, all right? Send her a galley. That's what this is. You know, Rosie O'Donnell feels conservative Christians, aggressive Christians are just as dangerous as, as Muslims, terrorists. OK? Radical Muslims. The term she used was radical Christians are just as dangerous to this country as radical Muslims. And she said that on The View.
Now, you gotta understand where she's coming from. Rosie O'Donnell is a secular progressive. She's in that -- she is a warrior, an S-P warrior. And I am an S-P traditional warrior. That's what Culture Warrior is all about. So you can't get a better window on the culture war in this country. Now, who's gonna win? Who's gonna win?
From the September 22 edition of ABC's The View:
ROBERTS: We have Rachael Ray on the show [20/20] tonight, and then Barbara Walters also has a revealing look at one of your favorite guys, Bill O'Reilly.
O'DONNELL: Bill. Lil' Billy. Billy from Long Island. I actually did his show once. Highly rated.
HASSELBECK: I remember.
ROBERTS (I think?): Highly rated.
O'DONNELL: Highly rated. That's what everyone tells me: "When you gonna go back on the highly rated show?" I'm like, you know --
BEHAR: How was it? Was it fun to be with him?
O'DONNELL: It was all right. You know, the guy grew up in Long Island. He went to the school where all the rich Catholic kids went, Chaminade. You know, and he always portrays himself as sort of a working-class kind of guy. I'm like, "But you went to Chaminade, so you aren't that working class." [inaudible]
BEHAR: Oh, I see.
HASSLEBECK: Maybe -- Maybe he had a grant or a scholarship to that little school.
O'DONNELL: I asked him; no, he didn't. But -- but you know, he's an interesting guy. I think it's much more fun to watch Stephen Colbert make fun of him --
O'DONNELL. -- than it is to sort of watch Bill, but you know --
OFF-SCREEN VOICE: That is fun.
ROBERTS: But, whatever you think about him, he's hugely popular and --
HASSELBECK: He is -- he's very popular.
BEHAR: He's a little grandiose. He thinks that Al Qaeda is after him. I mean, come on. They're in the mountains: "You know, I've got to get that Bill O'Reilly. I cannot stand him."
HASSELBECK: You know, he's actually going to be here next month.
O'DONNELL: What is up with that?
BEHAR: That's my all-purpose Al Qaeda accent.
HASSELBECK: You should do that for him, Joy, when he comes here next month.
O'DONNELL: You sounded like the Frito Bandito guy for a minute, you know. "I'm going to get Bill O'Reilly. I love the Fritos corn chips. I love them, I do."
From the September 25 edition of Fox News' The O'Reilly Factor:
O'REILLY: Today, this full-page ad appeared in the secular-progressive newspaper of record, The New York Times. The ad was a shot across the S-P bow. As they say in the land of the cliché, it's on.
Already, the S-P smear machine is cranked up. In tonight's "Most Ridiculous Item," we'll play you comments by Rosie O'Donnell and Jon Stewart. They're amusing. The hateful stuff I'm ignoring until tomorrow.
O'REILLY: Time now for "The Most Ridiculous Item of the Day." As I mentioned in the "Talking Points Memo," the smear-O'Reilly machine cranked up last week, because my book Culture Warrior was set to be released. Displays were pretty pathetic, the usual blather -- O'Reilly lies, that kind of thing. Bush lies, O'Reilly lies. Pass the Kool-Aid. Anyway, it's entertaining to see who buys into this propaganda. Rosie O'Donnell is number one.
O'DONNELL [video clip]: You know, the guy grew up in Long Island. He went to the school where all the rich Catholic kids went, Chaminade. You know, and he always portrays himself as sort of a working-class kind of guy. I'm like, "But you went to Chaminade, so you aren't that working class."
O'REILLY: Of course, the truth is my father broke his back to send me to Chaminade, a very fine school. Now, when I go on The View in a few weeks, I'm going to have Rosie read page 92 of Culture Warrior aloud.
From the September 25 edition of Westwood One's The Radio Factor:
O'REILLY: OK, so there's [Comedy Central's The Daily Show host Jon] Stewart. And it's true, we're all on the Al Qaeda hit list, but Stewart is very far down on it. OK? So you don't have to worry about it. All right. So, anyway, he's totally taking my remarks out of context. And that's OK. I mean, that's what Stewart does. He's got 15 writers, they come in every day, they do a half an hour at 11 o'clock Eastern time, and my rerun kicks their butt every night. Beats them silly. OK. Which brings me great satisfaction.
O'REILLY: OK. Well, you know, Rosie, with all due respect, is a blithering fool. And I'm going --
E.D. HILL (co-host): What do you mean, with all due respect, she's a blithering fool?
O'REILLY: With all due respect -- I'm gonna go on that show in a couple of weeks, and I will tell her that to her face. My father broke his back, broke his back, to send me to that school. Now on pages 92-95, on Culture Warrior in the book, I prove once and for all that Rosie and Al Franken and all these other assassins are, you know, full of you-know-what, four-letter word, and there it is. There's the proof. And there's pictures, there are pictures in the book to illustrate what I'm talking about.
O'REILLY: OK. Why? Why am I being too hard on them?
CALLER: Well, they both came on your show, and I think that, especially, Rosie had extremely good points about the gay adoption, and I think that Jon Stewart just being a good sport. And I think that you should give them both a little bit more respect instead of --
O'REILLY: All right. But I'm just joshing around with them the way they josh around with me. You know, let's face it. I have nothing against them. I like Stewart. O'Donnell, I don't really know.
HILL: But she had the guts to come on.
O'REILLY: She did. She came on and she was fine and everybody watched. And, you know, I respected her position and I wasn't disrespectful. But, look, if she's gonna say that I was a rich kid growing up, then she's not telling you the truth, and I gotta correct the record, [caller]. As for Stewart, you know, Stewart, we go back and forth all the time. You know, back, back, back, back, back. In fact, one of the great clips they used on the 20/20 piece on Friday was when I called Stewart a pinhead. That was great.
CALLER: And also, what's it gonna take to get people like Rosie O'Donnell and these other left-wing nutcases to open their eyes and see what is going on, Bill?
O'REILLY: You know, you're not gonna get them to say -- when I go on The View in a couple of weeks, I'm gonna say to Rosie O'Donnell -- I'm gonna say, "Listen, you made a comment that conservative Christians in America are just as dangerous as radical Islamists. Now you wanna explain that to me, madam?" I'm gonna say that. And, you know, but, look, I don't expect her to say, "You're right, Bill, I'm sorry. I shouldn't have done that," because she lives in that world. She lives in a world of overstatement.
Now, that comment, that bothered me a little bit. I have to be truthful; that bothered me a little bit. Because, look, I understand she's resentful toward the Christian right because they don't wanna give gays adoptions privileges and they don't want gays to get married. And she -- her -- that's her life now. She's a gay advocate. I understand why Rosie O'Donnell's angry with the Christian right. But to compare them to the fanatical Islamists who run around killing people, it's wrong, it's wrong. And, you know, you know me, the no spin guy. But I'm hoping we can have a few laughs too on the show. I hope it, you know, I don't wanna have to. I'm gonna be sitting between her and Joy Behar, my God. Jeez. What I do to sell this book, you know?
HILL: You're gonna -- you're gonna come out a changed man.
O'REILLY: No, I don't think so. I've been on there five times, and I've survived all times. I actually like going on the show. It's a lot of fun. 1-877-9NOSPIN. Let's take a quick break. We'll be back with more of your calls and comments in a moment.
- Network/Outlet
- Fox News Channel, Westwood One
- Person
- Bill O'Reilly
- Show/Publication
- The Radio Factor, The O'Reilly Factor
- Stories/Interests
- Attacks on Progressives, Propaganda/Noise Machine
Instructions for signing up and claiming your comment history are located here.
Updated rules for commenting are here.


text:
Fëanor invented the tengwar on the Valian Year 1250. strongly influenced by the Sarati of Rúmil the Loremaster.
Unlike Rúmil, Fëanor considered vowels as indepedent sounds and not just "colours" of the consonants, so he devised the "full writing" (Quanta Sarmë). However he also used a more 'conservative' system which seem to have been proved far more popular. Fëanor held the idea of syllabic analysis of the words by the Sarati, and made also use of signs for vowels (instead of the full letters).


text:
No Way To Protest
April 28, 2015 by 3 Comments
American Christianity's Blind Spot
July 24, 2012 by 4 Comments
The folks in the Facebook group "Christians Against the Tea Party" have made a quote from a recent blog post of mine into a poster once again. I am not used to this! [Read more…]


text:
Laura by Joan McGowan-Michael
Welcome! You are browsing as a guestWould you like to see 6 projects made from this pattern and much more? create a free account What am I missing?
© Joan McGowan-Michael
This pattern is available for $8.00.
From the designer:
The body of this lacy hooded pullover is based on our Shapely Tank pattern for a customized fit via short-row shaping.
The casual style is dressed up by working trim in beautiful hand-painted yarns.
In the upcoming months we will be adding styles based on this body. They will be our Shapely Options series. This is the first in the group.
For more information, see: http://www.whiteliesdesigns.com/patterns/lpullovers/...


text:
2 Min Read
LOS ANGELES (Reuters) - California corrections officials released a new photograph of imprisoned mass murderer Charles Manson on Thursday, showing the balding, gray-bearded killer at the age of 74.
The picture, which was taken at Corcoran State Prison in Central California, also reveals a glum Manson still bearing the swastika he carved into his forehead during his sensational 1970 murder trial.
Manson became one of the 20th century's most infamous criminals during the summer of 1969, when the Beatles-obsessed ex-con directed his mostly young, female followers to murder seven people.
Among the victims was eight-months pregnant actress Sharon Tate, the wife of filmmaker Roman Polanski. She was stabbed 16 times by members of the Manson Family in the early morning hours of August 9, 1969.
Four other people were also stabbed or shot to death in Tate's home that night by the group, who scrawled the word "Pig" in blood on the front door before leaving.
The following night members of the family stabbed Leno and Rosemary LaBianca to death, using their blood to write "Rise," "Death to Pigs" and "Healter Skelter" -- a misspelled reference to the Beatles song "Helter Skelter" -- on the walls and refrigerator door.
Manson was convicted and sentenced to death in 1971 but was spared execution when California abolished the death penalty the following year.
He has been denied parole 11 times and is next scheduled for a hearing in 2012.
Editing by Eric Walsh


text:
Vitamin A benefit
Vitamin A benefit
Vitamin A, also known as retinol, is essential to the formation of visual purple in the retina, which allows vision in dim light. Beta carotene, the precursor to vitamin A found in vegetables, has antioxidant properties, which means it protects cells from the daily toxic damage of oxidation.
A.D.A.M. content is best viewed in IE9 or above, Fire Fox and chrome browser.